Cue Biopharma (CUE) Accumulated Expenses (2017 - 2025)
Cue Biopharma (CUE) posted Accumulated Expenses of $783000.0 for Q4 2025, down 37.16% sequentially from $1.2 million in Q3 2025, and down 56.79% YoY from $1.8 million in Q4 2024.
Cue Biopharma (CUE) Accumulated Expenses (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Accumulated Expenses for 9 years, with the latest figure at $783000.0 in Q4 2025.
- Quarterly Accumulated Expenses fell 56.79% year-over-year to $783000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $783000.0 (down 56.79% YoY) and the FY2025 annual result came in at $783000.0, down 56.79% from the prior year.
- Accumulated Expenses declined to $783000.0 in Q4 2025 per CUE's latest filing, from $1.2 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $5.2 million in Q1 2024 and troughed at $783000.0 in Q4 2025.
- A 5-year average of $3.1 million and a median of $3.3 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 83.19% in 2024, then tumbled 66.73% in 2025.
- Over 5 years, Accumulated Expenses stood at $2.0 million in 2021, then gained by 13.28% to $2.3 million in 2022, then soared by 82.01% to $4.1 million in 2023, then tumbled by 56.2% to $1.8 million in 2024, then sank by 56.79% to $783000.0 in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $783000.0, $1.2 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 783,000.00 |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 4.23 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 3.20 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 4.14 Mn |
| Sep 30, 2023 | 5.13 Mn |
| Jun 30, 2023 | 4.08 Mn |
| Mar 31, 2023 | 2.84 Mn |
| Dec 31, 2022 | 2.27 Mn |
| Sep 30, 2022 | 3.88 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Mar 31, 2022 | 3.41 Mn |
| Dec 31, 2021 | 2.01 Mn |
| Sep 30, 2021 | 3.99 Mn |
| Jun 30, 2021 | 2.00 Mn |
| Mar 31, 2021 | 1.98 Mn |